JAZZ PHARMACEUTICALS PLC Aktie · IE00B4Q5ZN47 · JAZZ · A1JS1K (XNAS) Irland · Healthcare — Echtzeitkurse und Kurse, Unternehmensdaten, Dividenden, Fundamentaldaten und KI-gestützte Portfolio-Analyse auf MoneyPeak
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu JAZZ PHARMACEUTICALS PLC
Kein Kurs
18.05.2026 20:00
Aktuelle Kurse von JAZZ PHARMACEUTICALS PLC
| Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
|---|---|---|---|---|---|
NASDAQ |
JAZZ
|
USD
|
18.05.2026 20:00
|
229,55 USD
| 0,78 USD
+0,34 %
|
IEX |
JAZZ
|
USD
|
18.05.2026 19:59
|
229,57 USD
| 0,80 USD
+0,35 %
|
Quotrix |
JPPLCR47.DUSD
|
EUR
|
18.05.2026 05:27
|
195,65 EUR
| 5,25 EUR
+2,76 %
|
Hannover |
JPPLCR47.HANB
|
EUR
|
15.05.2026 06:03
|
193,25 EUR
| - |
Düsseldorf |
JPPLCR47.DUSB
|
EUR
|
14.05.2026 14:00
|
197,55 EUR
| - |
Hamburg |
JPPLCR47.HAMB
|
EUR
|
14.05.2026 06:05
|
198,60 EUR
| - |
Investierte Fonds
Folgende Fonds haben in JAZZ PHARMACEUTICALS PLC investiert:
Fonds | Vol. in Mio 135,19 | Anteil (%) 7,01 % |
Fonds | Vol. in Mio 433,94 | Anteil (%) 7,01 % |
Fonds | Vol. in Mio 818,09 | Anteil (%) 7,01 % |
Fonds | Vol. in Mio 334,21 | Anteil (%) 7,01 % |
Fonds | Vol. in Mio 14.731,70 | Anteil (%) 3,84 % |
Firmenprofil zu JAZZ PHARMACEUTICALS PLC Aktie
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Unternehmensdaten
Name JAZZ PHARMACEUTICALS PLC
Firma Jazz Pharmaceuticals plc
Symbol JAZZ
Website
https://www.jazzpharma.com
Heimatbörse
NASDAQ
NASDAQ
WKN A1JS1K
ISIN IE00B4Q5ZN47
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Renee D. Gala
Marktkapitalisierung 14 Mrd.
Land Irland
Währung USD
Mitarbeiter 2,8 T
Adresse Waterloo Exchange, 4 Dublin
IPO Datum 2007-06-01
Ticker Symbole
| Name | Symbol |
|---|---|
| Düsseldorf | JPPLCR47.DUSB |
| Frankfurt | J7Z.F |
| Hamburg | JPPLCR47.HAMB |
| Hannover | JPPLCR47.HANB |
| NASDAQ | JAZZ |
| Quotrix | JPPLCR47.DUSD |
Weitere Aktien
Investoren, die JAZZ PHARMACEUTICALS PLC halten, haben auch folgende Aktien im Depot: